Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma

Abstract

Background Prior hepatitis B virus infection (PBI) may increase the risk of developing hepatocellular carcinoma (HCC), but the impact of PBI on clinical outcomes following treatment for HCC remains unknown. The aim of this study was to clarify whether PBI affects clinical outcomes after liver resection for hepatitis C virus (HCV)-related HCC by retrospective cohort study. Methods PBI patients were defined as those negative for hepatitis B surface antigen and positive for anti-hepatitis B core antibody. Surgical outcomes of HCV-related HCC patients with PBI were compared to those without PBI. Survival of patients with non-B non-C HCC with and without PBI were also compared. Results In the HCV group, the median overall survival of 165 patients with PBI was 4.7 years (95% confidence interval [CI], 3.9–5.9), and was significantly shorter compared with 263 patients without PBI (6.6 years [5.3–9.8]; p = 0.015). Conversely, there was no significant difference in recurrence-free survival between the two groups (1.8 years [95% CI, 1.4–2.0] vs 2.0 years [1.7–2.3]; p = 0.205). On Cox proportional hazards regression model, independent factors for overall survival were PBI (hazard ratio 1.38 [95% CI, 1.02–1.87]; p = 0.033), multiple tumors ( p = 0.007), tumor size ( p = 0.002), and liver cirrhosis ( p < 0.001). On the other hand, in the non-B non-C HCC group, both the median overall survival (6.5 years [95% CI, 4.8–7.1]) and recurrence-free survival (2.4 years, [95% CI, 1.5–3.3]) in 104 patients with PBI were not significantly different from those (7.5 years [5.5 − NA; p = 0.932]; and 2.2 years [1.7–2.7; p = 0.983]) in 213 patients without PBI. Conclusions PBI and HCV in conjunction with each other affect the survival of patients that have undergone resection for HCC.

Diagnostic Value of Serum Biomarkers for Patients Undergoing Curative Resection with Non-B, Non-C Hepatocellular Carcinoma

“…The impact of HBcAb-positivity on the pathogenesis of NBNC HCC has been inconsistent (and even conflicting) in studies. Chronic HBV infection was considered to be the key determinant in most high-risk HCC areas (e.g., China, Eastern Africa) 4 and HBcAbpositivity had also been considered to be a promotion factor for the development of NBNC HCC, 8,16,17 according to gene-integration studies. [18][19][20][21] One study found that HBcAb-positive NBNC HCC had more advanced tumors than overt HBV (hepatitis B surface antigen positive) HCC, but their prognosis was relatively comparable.…”

Prognostic impact of hepatitis B virus infection in patients with primary cervical cancer

“…To our knowledge, this study is the first to reveal a prognostic value of PHI in primary cervical cancer. It has been reported that patients with PHI manifested a lower incidence of postoperative death and extrahepatic metastasis than those without PHI 18 . A previous meta‐analysis showed that in pancreatic cancer, the viral antigen/antibody pattern of PHI was not associated with higher risk 19 .…”

“…It has been reported that patients with PHI manifested a lower incidence of postoperative death and extrahepatic metastasis than those without PHI. 18 A previous meta-analysis showed that in pancreatic cancer, the viral antigen/antibody pattern of PHI was not associated with higher risk. 19 Some studies have also suggested that HBV vaccination is a positive predictor of cervical cancer, 20 and most patients with previous hepatitis B infection have acquired immunity, which may contribute to a better prognosis.…”

The significance of CDT1 expression in non-cancerous and cancerous liver in cases with hepatocellular carcinoma

“…( 4 ) All cases were closely monitored for recurrence of HCC at every postoperative outpatient visit until June, 2022. ( 12 ) The last observation analyzed in this study was June 29, 2022. The study design conformed to the ethical guidelines of the Declaration of Helsinki.…”

“…All cases were closely monitored for recurrence of HCC at every postoperative outpatient visit until January 2022. (12) For the exclusion criteria and definite diagnosis of postoperative HCC recurrence, please refer to our previous report. (4) The study design conformed to the ethical guidelines of the Declaration of Helsinki.…”